Mutations and prognosis in primary myelofibrosis-Reference-Cited by-同舟云学术

Mutations and prognosis in primary myelofibrosis

Published:2013-04-26 Issue:9 Volume:27 Page:1861-1869
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Vannucchi A M,Lasho T L,Guglielmelli P,Biamonte F,Pardanani A,Pereira A,Finke C,Score J,Gangat N,Mannarelli C,Ketterling R P,Rotunno G,Knudson R A,Susini M C,Laborde R R,Spolverini A,Pancrazzi A,Pieri L,Manfredini R,Tagliafico E,Zini R,Jones A,Zoi K,Reiter A,Duncombe A,Pietra D,Rumi E,Cervantes F,Barosi G,Cazzola M,Cross N C P,Tefferi A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013119.pdf

Reference48 articles.

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

2. Tefferi A . Myelofibrosis with myeloid metaplasia. N Eng J Med 2000; 342: 1255–1265.

3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901.

4. Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012; 119: 2657–2664.

5. Tefferi A . Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematology 2013; 88: 141–150.

Cited by 645 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis;Frontiers in Oncology;2024-08-30

3. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

4. SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?;Clinical Lymphoma Myeloma and Leukemia;2024-08

5. Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation;Transplantation and Cellular Therapy;2024-08